These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 35563176)

  • 21. Radiotherapy in nodal oligorecurrent prostate cancer.
    Pinkawa M; Aebersold DM; Böhmer D; Flentje M; Ghadjar P; Schmidt-Hegemann NS; Höcht S; Hölscher T; Müller AC; Niehoff P; Sedlmayer F; Wolf F; Zamboglou C; Zips D; Wiegel T
    Strahlenther Onkol; 2021 Jul; 197(7):575-580. PubMed ID: 33914101
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Local ablative stereotactic body radiotherapy for oligometastatic prostate cancer.
    Niazi T; Elakshar S; Stroian G
    Curr Opin Support Palliat Care; 2018 Sep; 12(3):351-358. PubMed ID: 29979320
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Toxicity and Efficacy of Local Ablative, Image-guided Radiotherapy in Gallium-68 Prostate-specific Membrane Antigen Targeted Positron Emission Tomography-staged, Castration-sensitive Oligometastatic Prostate Cancer: The OLI-P Phase 2 Clinical Trial.
    Hölscher T; Baumann M; Kotzerke J; Zöphel K; Paulsen F; Müller AC; Zips D; Koi L; Thomas C; Löck S; Krause M; Wirth M; Lohaus F
    Eur Urol Oncol; 2022 Feb; 5(1):44-51. PubMed ID: 34785189
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CyberKnife Stereotactic Ablative Radiotherapy as an Option of Treatment for Patients With Prostate Cancer Having Oligometastatic Lymph Nodes: Single-Center Study Outcome Evaluation.
    Napieralska A; Miszczyk L; Stąpór-Fudzińska M
    Technol Cancer Res Treat; 2016 Oct; 15(5):661-73. PubMed ID: 26208835
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stereotactic body radiotherapy versus conventional/moderate fractionated radiation therapy with androgen deprivation therapy for unfavorable risk prostate cancer.
    Patel SA; Switchenko JM; Fischer-Valuck B; Zhang C; Rose BS; Chen RC; Jani AB; Royce TJ
    Radiat Oncol; 2020 Sep; 15(1):217. PubMed ID: 32933541
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Consensus statements on ablative radiotherapy for oligometastatic prostate cancer: A position paper of Italian Association of Radiotherapy and Clinical Oncology (AIRO).
    D'Angelillo RM; Francolini G; Ingrosso G; Ravo V; Triggiani L; Magli A; Mazzeo E; Arcangeli S; Alongi F; Jereczek-Fossa BA; Pergolizzi S; Pappagallo GL; Magrini SM
    Crit Rev Oncol Hematol; 2019 Jun; 138():24-28. PubMed ID: 31092381
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcomes after a first and/or second salvage treatment in patients with oligometastatic prostate cancer recurrence detected by (18-F) choline PET-CT.
    Gomez-Iturriaga A; Casquero Ocio F; Ost P; Fernandez I; Rodeño E; Llarena R; Garcia-Olaverri J; Ortiz de Zarate R; Cacicedo J; Ahtamon A; Bilbao P
    Eur J Cancer Care (Engl); 2019 Sep; 28(5):e13093. PubMed ID: 31115124
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stereotactic body radiotherapy in oligometastatic prostate cancer patients with isolated lymph nodes involvement: a two-institution experience.
    Ingrosso G; Trippa F; Maranzano E; Carosi A; Ponti E; Arcidiacono F; Draghini L; Di Murro L; Lancia A; Santoni R
    World J Urol; 2017 Jan; 35(1):45-49. PubMed ID: 27233779
    [TBL] [Abstract][Full Text] [Related]  

  • 29. OLIGOPELVIS - GETUG P07: a multicentre phase II trial of combined salvage radiotherapy and hormone therapy in oligometastatic pelvic node relapses of prostate cancer.
    Supiot S; Rio E; Pacteau V; Mauboussin MH; Campion L; Pein F
    BMC Cancer; 2015 Sep; 15():646. PubMed ID: 26408012
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Manipulation of androgens and alterations in the androgen receptor axis in prostate cancer.
    Nguyen MM; Wang Z
    Minerva Urol Nefrol; 2008 Mar; 60(1):15-29. PubMed ID: 18427432
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stereotactic Ablative Radiotherapy for Prostate Cancer-The Treatment Results of 500 Patients and Analysis of Failures.
    Miszczyk L; Namysł-Kaletka A; Napieralska A; Kraszkiewicz M; Miszczyk M; Woźniak G; Stąpór-Fudzińska M; Głowacki G; Tukiendorf A
    Technol Cancer Res Treat; 2019 Jan; 18():1533033819870815. PubMed ID: 31462169
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A narrative review of oligometastatic prostate cancer-an evolving paradigm.
    Sritharan K; Rieu R; Tree A
    Ann Palliat Med; 2021 May; 10(5):5969-5987. PubMed ID: 33752437
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oligometastatic Hormone-Sensitive Prostate Cancer. Why Radiotherapy?
    Arcos MBL; López-Campos F; Valcarcel ML; Rubio MG; de Manzanos IVF; Duque-Santana V; Aparicio MG; Martin JZ; Kishan AU; Achard V; Siva S; Couñago F
    Clin Genitourin Cancer; 2023 Jun; 21(3):e93-e103. PubMed ID: 36456467
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial.
    Palma DA; Olson R; Harrow S; Correa RJM; Schneiders F; Haasbeek CJA; Rodrigues GB; Lock M; Yaremko BP; Bauman GS; Ahmad B; Schellenberg D; Liu M; Gaede S; Laba J; Mulroy L; Senthi S; Louie AV; Swaminath A; Chalmers A; Warner A; Slotman BJ; de Gruijl TD; Allan A; Senan S
    BMC Cancer; 2019 Aug; 19(1):816. PubMed ID: 31426760
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tissue prostate-specific antigen and androgen receptor immunoreactivity in prostate cancer biopsies before, during and after neo-adjuvant androgen deprivation followed by radiotherapy.
    Ogreid P; Berner A; Dahl O; Rettedal E; Fosså SD
    Eur Urol; 1999 Aug; 36(2):116-22. PubMed ID: 10420032
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Exploring All Avenues for Radiotherapy in Oligorecurrent Prostate Cancer Disease Limited to Lymph Nodes: A Systematic Review of the Role of Stereotactic Body Radiotherapy.
    Ponti E; Lancia A; Ost P; Trippa F; Triggiani L; Detti B; Ingrosso G
    Eur Urol Focus; 2017 Dec; 3(6):538-544. PubMed ID: 28801240
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Review of Stereotactic Body Radiation Therapy in the Management of Oligometastatic Prostate Cancer.
    Zhang B; Leech M
    Anticancer Res; 2020 May; 40(5):2419-2428. PubMed ID: 32366385
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stereotactic Ablative Radiotherapy Versus Low Dose Rate Brachytherapy or External Beam Radiotherapy: Propensity Score Matched Analyses of Canadian Data.
    Loblaw A; Pickles T; Crook J; Martin AG; Vigneault E; Souhami L; Cury F; Morris J; Catton C; Lukka H; Cheung P; Sethukavalan P; Warner A; Yang Y; Rodrigues G;
    Clin Oncol (R Coll Radiol); 2017 Mar; 29(3):161-170. PubMed ID: 27780694
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation therapy.
    Berkovic P; De Meerleer G; Delrue L; Lambert B; Fonteyne V; Lumen N; Decaestecker K; Villeirs G; Vuye P; Ost P
    Clin Genitourin Cancer; 2013 Mar; 11(1):27-32. PubMed ID: 23010414
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-Effectiveness Analysis of Stereotactic Ablative Radiation Therapy in Patients With Oligometastatic Cancer.
    Kumar A; Straka C; Courtney PT; Vitzthum L; Riviere P; Murphy JD
    Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1185-1194. PubMed ID: 33002541
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.